(350 days)
Not Found
No
The document describes standard image processing methods for noise reduction and tracking functionality, but does not mention AI or ML.
No.
The device is used for imaging (viewing, cross-sectional, and 3D imaging) of the eye, which is a diagnostic function, not a therapeutic one.
Yes
The device provides "axial cross sectional, and three-dimensional imaging of posterior ocular structures, including retina, macula, and optic disc, as well as imaging of anterior ocular structures, including the cornea, lens and anterior chamber angle," which is a form of diagnostic imaging.
No
The device description explicitly states that RESCAN 700 is Spectral Domain OCT technology integrated into a physical ophthalmic surgical microscope (Zeiss OPMI Lumera 700). It also mentions hardware components like a touch panel and foot control panel. While it uses software (CALLISTO eye) for control, data management, and image processing, the core device is a hardware-based imaging system.
Based on the provided information, the RESCAN 700 device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states that the RESCAN 700 is for "in vivo viewing, axial cross sectional, and three-dimensional imaging of posterior ocular structures... as well as imaging of anterior ocular structures...". This describes a device used for imaging structures within the living body (in vivo), not for examining specimens outside the body (in vitro).
- Device Description: The description reinforces its use with an ophthalmic surgical microscope and its function in providing intra-operative OCT images. This is consistent with an in vivo imaging device used during surgery.
- Lack of In Vitro Activities: There is no mention of the device being used to analyze biological samples (like blood, tissue, urine, etc.) or perform tests on these samples outside of the body.
- Clinical Study: The clinical study described involves obtaining images from participants during ocular surgery, which is an in vivo setting.
In summary, the RESCAN 700 is an ophthalmic imaging device used for visualizing structures within the eye during surgical procedures. This falls under the category of medical imaging devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
RESCAN 700 provides non-contact, high resolution, optical coherence tomographic (OCT) and biomicroscopic imaging of the anterior and posterior segment of the eye via an ophthalmic surgical microscope. The RESCAN 700 is indicated for in vivo viewing, axial cross sectional, and three-dimensional imaging of posterior ocular structures, including retina, macula, and optic disc, as well as imaging of anterior ocular structures, including the cornea, lens and anterior chamber angle. RESCAN 700 uses the assistance system (CALLISTO eye) that provides non-diagnostic video documentation and image capture for ophthalmic surgeries. The assistance system allows the remote control of RESCAN 700.
Product codes (comma separated list FDA assigned to the subject device)
OBO
Device Description
RESCAN 700 brings Spectral Domain OCT technology to the Zeiss OPMI Lumera 700 ophthalmic surgical microscope. Used in conjunction with the assistance system, CALLISTO eye, OCT images taken intra-operatively are presented on the monitor and may also be seen within the surgeon's oculars using the OPMI Lumera 700's integrated data injection system (IDIS). OCT images may be stored for subsequent retrieval using CALLISTO eye's data management system. RESCAN 700 can be controlled via the touch panel of the assistance system or via the foot control panel of an ophthalmic surgical microscope.
The proposed RESCAN 700 device and its primary functionality remain unchanged from the previously cleared device while including the following modifications:
- Improvement of OCT Visualization: To improve the visual appearance of the live OCT images, the standard image processing methods for noise reduction were optimized.
- Increased Power of OCT Beam: The power of the OCT Beam was increased from 490 µW to 620 µW to improve the signal-to-noise ratio.
- Increased Scan Depth: The scan depth was increased to provide images at a scan depth of 2.9 mm or 5.8 mm.
RESCAN 700 is used with CALLISTO eye Software version 3.6. CALLISTO eye Software version 3.6 is an assistance, information, and documentation system to support ophthalmic surgical procedures. CALLISTO eye software operates as an adjunct to the OPMI Lumera family of ophthalmic surgical microscopes to process real-time videos and OCT data (B-Scan images). CALLISTO eye must be installed on a touchscreen Panel PC; the Panel PC is offered as an accessory.
In conjunction with RESCAN 700 the following modifications were added to CALLISTO eye Software version 3.6:
- Ability to record surgical videos directly to a connected USB hard drive.
- The OCT function was enhanced by adding OCT XY-tracking for the Scan Location Marker. The functionality is similar to the Z-tracking function but works in the XY-plane instead of the Z-axis.
Mentions image processing
Yes, "To improve the visual appearance of the live OCT images, the standard image processing methods for noise reduction were optimized."
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Optical Coherence Tomography (OCT), biomicroscopic imaging
Anatomical Site
anterior and posterior segment of the eye, posterior ocular structures (retina, macula, and optic disc), anterior ocular structures (cornea, lens and anterior chamber angle)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Ophthalmic surgical microscope, ophthalmic surgeries
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical study was conducted to compare visualization quality of relevant posterior- and anterior-segment ocular structures during ocular surgery from OCT images between two RESCAN 700 systems using different software versions at the three available scan depths (2.0 mm [predicate device], 2.9 mm, 5.8 mm). Obtained images were anonymized and graded for clinical utility in a randomized order by three independent, masked graders using a pre-specified grading scale. A total of 22 participants were enrolled (11 with corneal conditions, seven with glaucoma, four with retina conditions) and 84 images were obtained.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing was conducted on the subject device to address modifications on RESCAN 700. Existing performance testing remains valid. The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
RESCAN 700 was designed and tested to the applicable standards for electrical and optical safety and verified to established standards. Testing of the device with RESCAN 700, OPMI Lumera 700 and CALLISTO eye Panel PC was conducted to demonstrate conformance to the third edition of 60601-1 in addition to the IEC 60601-1-2 standard for electromagnetic compatibility.
RESCAN 700 and CALLISTO eye conform to the applicable FDA recognized and international IEC and ISO standards with regards to performance and safety.
In addition to systems testing, software verification activities completed were divided into three phases:
- Tests accompanying development (including code inspections)
- Integration test phase - stabilization phase
- System verification
Verification and validation activities were successfully completed and prove that RESCAN 700 and CALLISTO eye meet their requirements and perform together as intended.
Clinical performance testing: A clinical study was conducted to compare visualization quality of relevant posterior- and anterior-segment ocular structures during ocular surgery from OCT images between two RESCAN 700 systems using different software versions at the three available scan depths (2.0 mm [predicate device], 2.9 mm, 5.8 mm). Obtained images were anonymized and graded for clinical utility in a randomized order by three independent, masked graders using a pre-specified grading scale. A total of 22 participants were enrolled (11 with corneal conditions, seven with glaucoma, four with retina conditions) and 84 images were obtained. All images were successfully assessed by all graders, with fair to good concordance between graders. Image quality was similar between the 2.0 mm and 2.9 mm scan depths in the corneal and glaucoma surgery sub-groups. Scans at the 2.9 mm scan depth were rated slightly higher than those at the 2.0 mm scan depth in the retinal surgery sub-group. Scans at 5.8 mm were rated lower than those at 2.0- and 2.9-mm scan depths in the corneal and glaucoma surgery sub-groups. In summary, the results demonstrate that OCT image quality at the new scan depth of 2.9 mm is acceptable. Images at the 5.8 mm scan depth may allow for a view of ocular structures with additional spatial context at the expense of finer detail.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
RESCAN 700, K141844, CIRRUS photo, K112184
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the FDA acronym in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and the word "ADMINISTRATION" in a smaller font size below.
January 11, 2019
Carl Zeiss Meditec AG % Mandy Ambrecht Staff Regulatory Affairs Specialist Carl Zeiss Meditec, Inc. 5160 Hacienda Drive Dublin, CA 94568
Re: K180229
Trade/Device Name: RESCAN 700, CALLISTO eye Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: OBO Dated: December 7, 2018 Received: December 10, 2018
Dear Mandy Ambrecht:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmp/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.qov
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely yours.
Bradley S. Cunningham -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180229
Device Name RESCAN 700
Indications for Use (Describe)
RESCAN 700 provides non-contact, high resolution, optical coherence tomographic (OCT) and biomicroscopic imaging of the anterior and posterior segment of the eye via an ophthalmic surgical microscope. The RESCAN 700 is indicated for in vivo viewing, axial cross sectional, and three-dimensional imaging of posterior ocular structures, including retina, macula, and optic disc, as well as imaging of anterior ocular structures, including the cornea, lens and anterior chamber angle.
RESCAN 700 uses the assistance system (CALLISTO eye) that provides non-diagnostic video documentation and image capture for ophthalmic surgeries. The assistance system allows the remote control of RESCAN 700.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY (per 21 CFR §807.92)
RESCAN 700
GENERAL INFORMATION
| Manufacturer: | Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52
07745 Jena, Germany
+49 7364 206985
+49 7364 954432 |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Mandy Ambrecht
Senior Staff Regulatory Affairs Specialist
Carl Zeiss Meditec, Inc.
5160 Hacienda Drive
Dublin, California 94568
(925) 557-4561 (phone)
(925) 557-4259 (fax) |
| Date Summary Prepared: | January 3, 2019 |
| Classification name | Ophthalmoscope |
| Classification | 886.1570 |
| Class | II |
| Product Code | OBO |
| Trade / Proprietary Name | RESCAN 700 |
| Common Name | Tomography, Optical coherence |
| Primary Predicate Device
Company:
Device: | Carl Zeiss Meditec AG
RESCAN 700, K141844 |
| Secondary Predicate Device
Company:
Device: | Carl Zeiss Meditec AG
CIRRUS photo, K112184 |
4
INDICATIONS FOR USE (21 CFR §807.92(a)(5))
RESCAN 700
RESCAN 700 provides non-contact, high resolution, optical coherence tomographic (OCT) and biomicroscopic imaging of the anterior and posterior segment of the eye via an ophthalmic surgical microscope. The RESCAN 700 is indicated for in vivo viewing, axial cross sectional. and three-dimensional imaging of posterior ocular structures, including retina, macula, and optic disc, as well as imaging of anterior ocular structures, including the cornea, lens and anterior chamber angle.
RESCAN 700 uses the assistance system (CALLISTO eye) that provides non-diagnostic video documentation and image capture for ophthalmic surgeries. The assistance system allows the remote control of RESCAN 700.
DEVICE DESCRIPTION (21 CFR §807.92(a)(4))
RESCAN 700
RESCAN 700 brings Spectral Domain OCT technology to the Zeiss OPMI Lumera 700 ophthalmic surgical microscope. Used in conjunction with the assistance system, CALLISTO eye, OCT images taken intra-operatively are presented on the monitor and may also be seen within the surgeon's oculars using the OPMI Lumera 700's integrated data injection system (IDIS). OCT images may be stored for subsequent retrieval using CALLISTO eye's data management system. RESCAN 700 can be controlled via the touch panel of the assistance system or via the foot control panel of an ophthalmic surgical microscope.
Product Update: RESCAN 700
The proposed RESCAN 700 device and its primary functionality remain unchanged from the previously cleared device while including the following modifications:
Improvement of OCT Visualization ●
To improve the visual appearance of the live OCT images, the standard image processing methods for noise reduction were optimized.
. Increased Power of OCT Beam
The power of the OCT Beam was increased from 490 µW to 620 µW to improve the signal-to-noise ratio.
Increased Scan Depth ●
The scan depth was increased to provide images at a scan depth of 2.9 mm or 5.8 mm.
5
RESCAN 700 is used with CALLISTO eye Software version 3.6.
CALLISTO eye Software version 3.6 is an assistance, information, and documentation system to support ophthalmic surgical procedures. CALLISTO eye software operates as an adjunct to the OPMI Lumera family of ophthalmic surgical microscopes to process real-time videos and OCT data (B-Scan images). CALLISTO eye must be installed on a touchscreen Panel PC; the Panel PC is offered as an accessory.
In conjunction with RESCAN 700 the following modifications were added to CALLISTO eye Software version 3.6.
- Ability to record surgical videos directly to a connected USB hard drive. ●
- The OCT function was enhanced by adding OCT XY-tracking for the Scan Location Marker. The functionality is similar to the Z-tracking function but works in the XY-plane instead of the Z-axis.
Table 5-1 presents the functions offered by the previous and proposed CALLISTO eye with a focus on the interaction with RESCAN 700.
| CALLISTO eye Functions | SW
Version
3.2 | SW
Version
3.6 |
|--------------------------------------------------------------------|----------------------|----------------------|
| as cleared in premarket notification | K141844 | |
| Network connectivity | X | X |
| User management | X | X |
| Updated
Patient management | X | X |
| Surgery documentation (video recording and still
images) | X | X |
| Ophthalmic surgical microscope remote control
(OPMI LUMERA 700) | X | X |
| Live video | X | X |
| Eye tracking | | X |
| New
Export of OCT data to connected PACS system
(FORUM)* | | X |
Table 5-1: CALLISTO eye Functions by Software Version (Note: The functionality marked with an asterisk (*) is not the subject of this 510(k) Premar
6
| CALLISTO eye Functions | SW
Version
3.2 | SW
Version
3.6 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|
| as cleared in premarket notification | K141844 | |
| Updated
Control of the RESCAN 700 (OCT Camera)
connected to the OPMI LUMERA 700 | X | X |
| Visualization of optical coherence tomography
(OCT) data | X | X |
| Capture and review of OCT data
(images and B-scans) | X | X |
| Support of 1-Line, 2-Line (OCT cube) and
5-Line OCT data | X | X |
| New
XY-tracking support for Scan Location Marker
(for OCT views based on vessels) | | X |
| New
Support for 2.9 mm and 5.8 mm scan depths | | X |
| New
Default combination of scan length and scan
depth. | | X |
| Updated
Combined full screen mode for microscope live
video and OCT live view | | X |
| New
Icon-based ocular overlays to visualize the
provided information (“Cockpits”) in the data
injection system of the connected microscope | | X |
| Import / Export of patient treatment data to a
USB storage device | X | X |
| New
USB recording: Surgery documentation can be
recorded in parallel to a USB hard drive | | X |
RISK MANAGEMENT
Risk management is ensured via a risk analysis, which is used to identify potential hazards and mitigations. These potential hazards are controlled by design means, protection measures and user instructions. To confirm that the measures are effective and that the product meets its intended uses, verification of requirements and standards, and validation of the clinical workflow was performed. Carl Zeiss Meditec adheres to recognized and established industry practice and relevant international standards where indicated.
7
PERFORMANCE DATA & SUMMARY OF VERIFICATION AND VALIDATION ACTIVITY (21 CFR §807.92(B))
Performance testing was conducted on the subject device to address modifications on RESCAN 700. Existing performance testing remains valid. The results from each set of tests demonstrate that the device performs as intended and is thus substantially equivalent to the predicate devices to which it has been compared.
RESCAN 700 was designed and tested to the applicable standards for electrical and optical safety and verified to established standards. Testing of the device with RESCAN 700, OPMI Lumera 700 and CALLISTO eye Panel PC was conducted to demonstrate conformance to the third edition of 60601-1 in addition to the IEC 60601-1-2 standard for electromagnetic compatibility.
RESCAN 700 and CALLISTO eye conform to the applicable FDA recognized and international IEC and ISO standards with regards to performance and safety (see Table 5-2).
| FDA Recognized Standards | |
|---|---|
| Identification | Description |
| ISO 14971: 2007 | Medical Devices – Application of Risk |
| Management to Medical Devices | |
| ANSI/AAMI ES60601- | |
| 1:2005/(R)2012 and A1:2012, | |
| C1:2009/(R)2012 and | |
| A2:2010/(R)2012 | Electrical equipment -- Part 1: General |
| requirements for basic safety and essential | |
| performance | |
| IEC 60601-1-2:2014 | Medical electrical equipment - Part 1-2: |
| General requirements for basic safety and | |
| essential performance - Collateral standard: | |
| Electromagnetic compatibility - Requirements | |
| and tests | |
| IEC 60601-1-6:2013 | Medical electrical equipment - Part 1-6: |
| General requirements for basic safety and | |
| essential performance - Collateral standard: | |
| Usability | |
| IEC 62366-1:2015 | Medical devices – Application of usability |
| engineering to medical devices | |
| ISO 10936-2:2010 | Optics and photonics - Operation microscopes |
- Part 2: Light hazard from operation
microscopes used in ocular surgery |
| ISO 15004-2:2007 | Ophthalmic Instruments - Fundamental
requirements and test methods Part 2: Light
hazard protection |
Table 5-2: FDA Recognized Standards
8
| FDA Recognized Standards | |
|---|---|
| Identification | Description |
| IEC 62471:2006 | Photobiological safety of lamps and lamp |
| systems | |
| IEC 62304:2015 | Medical device software - Software life cycle |
| processes | |
| NEMA PS 3.1-3.20 | Digital Imaging and Communications in |
| Medicine (DICOM) |
In addition to systems testing, software verification activities completed were divided into three phases:
- Tests accompanying development (including code inspections)
- Integration test phase - stabilization phase
- System verification ●
Verification and validation activities were successfully completed and prove that RESCAN 700 and CALLISTO eye meet their requirements and perform together as intended.
Clinical performance testing
A clinical study was conducted to compare visualization quality of relevant posterior- and anterior-segment ocular structures during ocular surgery from OCT images between two RESCAN 700 systems using different software versions at the three available scan depths (2.0 mm [predicate device], 2.9 mm, 5.8 mm). Obtained images were anonymized and graded for clinical utility in a randomized order by three independent, masked graders using a pre-specified grading scale. A total of 22 participants were enrolled (11 with corneal conditions, seven with glaucoma, four with retina conditions) and 84 images were obtained. All images were successfully assessed by all graders, with fair to good concordance between graders. Image quality was similar between the 2.0 mm and 2.9 mm scan depths in the corneal and glaucoma surgery sub-groups. Scans at the 2.9 mm scan depth were rated slightly higher than those at the 2.0 mm scan depth in the retinal surgery sub-group. Scans at 5.8 mm were rated lower than those at 2.0- and 2.9-mm scan depths in the corneal and glaucoma surgery sub-groups. In summary, the results demonstrate that OCT image quality at the new scan depth of 2.9 mm is acceptable. Images at the 5.8 mm scan depth may allow for a view of ocular structures with additional spatial context at the expense of finer detail.
TECHNOLOGICAL CHARACTERISTICS (21 CFR §807.92(a)(6)) AND SUBSTANTIAL EQUIVALENCE (21 CFR §807.92(a)(3))
It is the opinion of Carl Zeiss Meditec AG that the proposed device, RESCAN 700 is substantially equivalent to RESCAN 700 (K141844) and CIRRUS photo (K112184) with regards to indications for use. RESCAN 700 and CIRRUS photo are both intended to provide OCT images of the anterior and posterior segment of the eye. Both devices employ a noninvasive, non-contact low-coherence interferometry technique to generate cross-sectional images of internal ocular tissue microstructures by measuring optical reflections from tissue.
9
Both devices obtain high-resolution images using spectral domain optical coherence tomography.
Differences with the proposed device include modifications to improve visualization constituting increased OCT power that remains below the level of CIRRUS photo and increased scan depth.
The proposed product, RESCAN 700, will be used with CALLISTO eye, Software version 3.6. The predicate device, RESCAN 700, was used with CALLISTO eye Software version 3.2 (K141844). Both versions of CALLISTO eye provide non-diagnostic video documentation and image capture for ophthalmic surgeries and allow remote control of the surgical microscope.
Both products inject information such as light, zoom and recording into the right ocular; the proposed device uses "Cockpits", icon-based ocular overlays to visualize the provided information in the data injection system of the connected microscope.
SUMMARY (21 CFR §807.92(b)(3))
RESCAN 700 has the same intended use and technological characteristics as the predicate devices, RESCAN 700 (K141844) and the same intended use as CIRRUS photo (K112184). RESCAN 700 was and continues to be used with CALLISTO eye.
The modifications to the RESCAN 700 device were implemented to improve OCT visualization while remaining compliant with the applicable standards for optical light hazards. These modifications do not raise new issues of safety or effectiveness. Therefore, ZEISS believes that the subject device, RESCAN 700 is substantially equivalent to the predicate devices, RESCAN 700 (K141844) and CIRRUS photo (K112184).